Defymed's mission is to develop innovative medical devices for diabetic patients providing effective treatments and improving quality of life
million diabetics worldwide forecasted for 2035
billion per year spent on diabetes-related expenses
more than 10
million diabetics receiving insulin therapy have poorly regulated blood glucose levels
July 10 2017
Strasbourg, 10th July 2017: Targeted at persons suffering from diabetes (Type 1 diabetics and some T...
June 12 2017
Strasbourg, 12th June 2017 : BIOSID is an European project coordinated by the European Diabetes Stud...
May 04 2017
11-12 May 2017: Defymed will be present at the JDRF Encapsulation Consortium that will be held in New York – USA. Defymed will present the latest results on MailPan®’s Bioartificial Pancreas development. This privileged group gathers worldwide key opinion leaders in the field of Cell therapy and Encapsulation for the treatment of Type1 Diabetes. For more inf...